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INTRODUCTION
Filamentous bacteriophage predominantly infect Gram-negative bacteria and make an important
contribution to host physiology, ecology, and virulence, including production of deadly toxins,
such as cholera toxin. The unique filamentous structure, small genome size (4–12 kbp), replicative
and/or integrativemode of inheritance, simple cultivation, and easy genomicmanipulation sparked
considerable attention to this class of bacteriophage for a number of applications, including cloning,
sequencing, recombinant protein expression, phage display technology, and nanotechnology. This
book covers a range of topics that can be grouped into two themes: impact of diverse filamentous
phage on their host bacteria (five chapters) and applications of Escherichia coli Ff phage (eight
chapters).
IMPACT OF DIVERSE FILAMENTOUS PHAGE ON THE HOST
BACTERIA
Five articles explore diverse filamentous bacteriophage, including identification, replication,
integration into the host chromosome, and effect on their bacterial host properties, such as growth
rate, biofilm dynamics, and virulence.
Nagayoshi et al. describe the first fully sequenced hyperthermophilic filamentous phage,
8OH3, discovered in geothermal water. This phage infects the thermophilic bacterium Thermus
thermophilus HB8. Ahmad et al. identify and describe a novel filamentous phage isolated from
soil. The phage, named XacF1, causes loss of virulence in Xanthomonas axonopodis pv. citri, the
causative agent of citrus canker, and could potentially be used for treatment or prevention of this
disease.
Both XacF1 and 8OH3 replicate efficiently and form turbid plaques due to increase of the host
generation time, but do not kill the host. Lack of the host killing is intrinsic to the secretion-
like process of filamentous phage assembly and release, while the superinfection is prevented due
to the blocking of primary and secondary host receptors by the production of phage-encoded
receptor-binding protein pIII in the infected cells. One exception to these universally accepted rules
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is prophage Pf4 of Pseudomonas aeruginosa PAO1. This
phage converts into a “superinfective” form within the mature
P. aeruginosa biofilms, infecting and killing the surrounding
prophage-containing cells. Here, Hui et al. identify a role of
reactive oxygen or nitrogen species DNA-damaging activities
in the formation of superinfective phage, providing a link to
the observed high-frequency mutations in the gene encoding
repressor of Pf4 phage replication in the mature P. aeruginosa
biofilms.
In contrast to the phage described above, filamentous phage
Ypf8 of the plague bacillus Yersinia pestis replicates poorly,
yet allows better colonization of the mammalian host in
comparison to the phage-free strain. Derbise and Carniel review
the intertwined microevolution of Y. pestis and Ypf8 over the
past 3000 years. Some peculiarities of this phage include its broad
host spectrum, elusive host receptor(s), and hard-to-reconcile
pattern of seemingly exclusively episomal or integrated states in
closely related Y. pestis strains.
Most lysogenic filamentous phage rely on a host-encoded
XerCD recombinase for integration into highly conserved dif
sites of bacterial chromosomes; however the mechanisms of
integration and prophage biology vary widely. Das reviews
the integration mechanisms of three lysogenic filamentous
vibriophage (CTX8, VGJ8, and TLC8) into the Vibrio cholerae
chromosomes. Variation in DNA sequences of attP sites in the
phage genomes drives differences in the integration and excision
mechanisms, which ultimately impact on the lysogen activation,
prophage replication, and efficiency of phage production. This
review therefore outlines how the attP sites in a filamentous
phage can be used to predict integration/replication modes of
filamentous prophage and conversely, how the engineered attP
sites can be used to design novel types of chromosomally-
integrated bacterial expression vectors.
APPLICATIONS OF THE FF FILAMENTOUS
PHAGE
Eight chapters in this book review or report recent applications
and technological innovations involving Ff phage of E. coli,
or derived particles. Phage display is the most prominent
application of filamentous phage. It was developed on the
shoulders of versatile cloning vectors derived from the E. coli
Ff (F-pilus specific) filamentous phage (f1, fd, and M13), and
knowledge about their life cycle. Combinatorial technologies
including Ff phage display are based on a physical link of
coding sequence to encoded protein displayed on the virus
particle. Screening vast Ff display libraries for variants that
bind a “bait” of interest has resulted over the past 25 years in
identification of bioactive peptides or therapeutic recombinant
antibodies. Two chapters, by Gagic et al. and Henry et al., review,
respectively, phage display applications for discovery ofmicrobial
surface proteins (including vaccine targets) and non-traditional
applications of phage particles as therapeutic biologics, vaccines
carriers, or bioconjugation scaffolds.
A technology report (Tjhung et al.) addresses an issue that has
plagued phage display libraries of proteins and peptides fused
to the N-terminus of virion protein pIII, in that some peptide
variants are more likely to be degraded than others. Recombinant
phage encoding these degradable variants have advantage at
amplification step over other library clones, due to more efficient
pIII-mediated infection of the host, and may outcompete the
true binders in the library screens. The authors demonstrate
that this can be prevented by displaying peptides between the
pIII N1 and N2 domains instead of display at the N-terminus.
Given that N1 domain is essential for infection, amplification of
recombinant phage clones depends on preservation of displayed
peptide (and thereby retention of the N1 domain in the phage).
This strategy eliminates those recombinant clones in the library
whose displayed peptides are degraded. It is very likely that phage
display between N1 and N2 domains of pIII will be taken up by
many researchers in the future.
Two research reports describe novel applications of Ff-phage-
derived particles in tumor targeting. Gillespie et al. describe
a new approach for assembly of tumor-targeting drug-loaded
liposomes, by enabling spontaneous insertion of cancer-cell-
binding peptide-pVIII fusion protein. The insertion via pVIII
hydrophobic core without damaging the liposome was achieved
by applying a novel method for direct purification from the phage
particles, using 2-propanol. This protocol greatly simplifies the
assembly of cancer-targeting drug-loaded liposomes, allowing
screening of multiple peptides for targeting efficiency and drug
delivery. Dor-On and Solomon report brain tumor targeting by
naked Ff phage (not displaying any brain-targeting peptides)
in a mouse model of glioblastoma after intranasal application.
Interestingly, particle-associated lipopolysaccharides may be the
key to brain targeting and anti-tumor activity of Ff in this model.
Three reports describe applications of Ff phage as
nanoparticles. Sattar et al. report development of a method to
functionalize and efficiently produce extremely short Ff-derived
particles (50 nm in length) that contain no genes or antibiotic
markers. The authors show that the short particles perform better
than the full-length phage of the same composition as diagnostic
particles in lateral-flow diagnostic assays. In a short review,
Bernard and Francis discuss modifications that are essential
for applications of Ff phage as functionalized nanoparticles.
These include chemical conjugation to organic molecules such as
fluorophores, pigments, carbohydrates, or inorganic molecules.
One fascinating property of filamentous phage is that they are
liquid crystals at high concentrations. Review by Dogic gives a
clear, biologist-friendly, and up-to-date account of the liquid
crystalline properties filamentous phage and their applications in
the soft matter physics.
PERSPECTIVE
Future holds discovery of many novel filamentous phage.
Some of these will likely be used as genetic tools for
bacterial engineering, utilizing knowledge about their attP sites,
integration, and replication. Many filamentous phage modulate
bacterial pathogenicity, hence therapeutic interventions against
pathogenic bacteria, based on known and novel filamentous
bacteriophage, are eagerly anticipated. Filamentous phage of
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innocuous bacteria other than currently used Ff (f1, fd, and
M13) will find applications in biotechnology, biomedicine, and
nanotechnology, allowing exploration of novel properties, with
the aim of decreasing the production cost and environmental
footprint. Upscaling and eliminating safety concerns (removal
of antibiotic-resistance genes and ability to replicate) will
allow transition of filamentous-phage-particle-based technology
from the laboratory containment to the consumer. In parallel,
filamentous-phage-derived particles of ever more imaginative
functions or physical properties will be designed and assembled
into advanced nanostructures and nanomachines.
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